Medivizor

Title of notification

Here comes the notification
X
 
icon
colorectal cancer | Clinical Trial | Added Nov 22, 2020

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment.

icon
icon
colorectal cancer | Research | Treatment | 10 pages | source: PLOS ONE | Added Nov 19, 2020

Evaluating timing between chemoradiotherapy and surgery in patients with rectal cancer.

This trial was carried out to examine the optimal time interval between completing chemoradiotherapy (CRT) and robotic-assisted surgery (RAS) in patients with rectal cancer. The trial found that RAS is safe and effective after 10-12 weeks of CRT.

icon
colorectal cancer | Research | 10 pages | source: Colorectal Disease | Added Nov 17, 2020

Colorectal cancer surgery and long-term health related quality of life with remote follow-up

This study investigated the long-term health-related quality of life (HQL) after colorectal cancer (CRC) surgery. Researchers suggested that overall long-term HQL was good, although some patients may need closer follow-up.

icon
icon
colorectal cancer | Research | Treatment | 10 pages | source: Clinical Colorectal Cancer | Added Oct 26, 2020

Evaluating the timing of chemotherapy plus bevacizumab for patients with colorectal cancer and liver metastasis

This study investigated whether chemotherapy plus bevacizumab (Avastin) before and after or after surgery improves the survival of patients with colorectal cancer (CRC) and operable liver metastasis (LM; cancer spread to the liver). Researchers suggested that chemotherapy and bevacizumab before and after surgery improved the overall survival of these patients.

icon
colorectal cancer | Research | 10 pages | source: British Journal of Cancer | Added Oct 24, 2020

Vitamin D supplementation improves survival in patients with colorectal cancer

This study investigated if vitamin D supplementation improves colorectal cancer (CRC) survival outcomes. Researchers suggested that vitamin D supplementation is associated with improved survival in CRC.

icon
colorectal cancer | Research | 10 pages | source: Journal of clinical oncology | Added Oct 13, 2020

Evaluating Immunoscore as a prognostic factor in stage 3 colon cancer

This study investigated Immunoscore (IMS) as a prognostic tool in patients with stage 3 colon cancer. Researchers suggested that a high IMS is associated with prolonged survival in these patients.

icon
icon
colorectal cancer | Research | Treatment | 10 pages | source: International Journal of Colorectal Disease | Added Oct 04, 2020

Three different treatments for metastatic colorectal cancer: a comparison.

This study compared the effectiveness of three different treatments for metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that fruquintinib (Elunate) was associated with the best treatment outcomes.

icon
icon
colorectal cancer | Research | Treatment | 10 pages | source: Advances in therapy | Added Sep 30, 2020

Comparing regorafenib plus chemotherapy to other biological drugs for the second-line treatment of metastatic colorectal cancer

This analysis was carried out to look at including regorafenib (Stivarga) in second-line therapy for patients with metastatic colorectal cancer (mCRC). The authors found that regorafenib in combination with chemotherapy might be an alternative to standard second-line treatment options for these patients.

icon
icon
colorectal cancer | Research | Treatment | 10 pages | source: Journal of clinical oncology | Added Sep 19, 2020

FOLFOXIRI plus bevacizumab improves survival of patients with advanced colorectal cancer

This study compared the survival outcomes of different chemotherapy treatments in patients with inoperable advanced colorectal cancer (CRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) significantly improved the survival of these patients.

icon
icon
colorectal cancer | Research | Treatment | 10 pages | source: Journal of clinical oncology | Added Sep 09, 2020

Bevacizumab plus mFOLFOX6 improves the outcomes of patients with colorectal cancer and liver metastasis

This study investigated the effects of bevacizumab (Avastin) combined with mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) treatment in RAS-positive advanced colorectal cancer (CRC). Researchers suggested that this treatment improved the treatment and survival outcomes of patients with CRC and liver metastasis (spread to the liver).

View

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?